ArticleOrphanet journal of rare diseases2025
Pulmonary features and stage of disease in adult patients with hyper-IgE syndrome: a single-centre clinical study and literature review.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Case Report:Frontiers in pediatrics · 2026Article
- Article
- STAT3 c.1915C > T variant-associated Hyper-IgE syndrome in a child: a case report.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe hyper-IgE syndromes (HIES) are a heterogeneous group of inborn errors of immunity-sharing manifestations including increased infection susceptibility, eczema, and raised serum IgE. Pulmonary complications are responsible for high morbidity and mortality rates in patients with HIES. This study examines the progression of pulmonary disease in adult patients with HIES and compares the subsequent findings with existing literature.
methodsTen adult patients with HIES diagnosed at Peking Union Medical College Hospital (PUMCH) from January 2016 to October 2023 were included in this study. Diagnosis was confirmed using the National Institutes of Health (NIH) criteria and whole-exome sequencing. Clinical data on pulmonary disease progression, microbiology, imaging and histology were collected. A systematic literature review was conducted for comparison.
resultsRecurrent pulmonary infections led to significant structural lung damage, with 90.0% (9/10) of patients developing bronchiectasis and pneumatocele. Early infections (0-10 years) were predominantly due to Staphylococcus aureus (80.0%,8/10), while later stages (6-22 years) showed a shift to more complex infections with Aspergillus/fungus (70.0%,7/10), Mycobacterium tuberculosis (50.0%, 5/10), and Pseudomonas aeruginosa (40.0%, 4/10). Imaging revealed extensive bronchiectasis and pneumatocele formation. Histological examinations demonstrated acute inflammation (40%, 2/5), granuloma formation (80%, 4/5), and eosinophilic infiltration (100%, 5/5). Comparatively, our findings are consistent with previous reports that suggest a higher incidence of pulmonary structural damage in patients with the signal transducer and activator of the transcription 3 (STAT3) mutations than in those with other gene variants. However, our cohort showed a faster progression from initial infection to structural damage, highlighting the need for early intervention.
conclusionThe progression of pulmonary disease in HIES patients underscores a critical three-step process: initial recurrent infections, development of structural lung damage, and subsequent reinfections that aggravate the damage. This rapid transition from infection to structural damage, especially in patients with STAT3 mutations, highlights the importance of early and aggressive intervention. Managing reinfections after structural lung damage is essential to prevent further deterioration and to improve long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.